L M Laiglesia1,2, S Lorente-Cebrián1,2,3, L Martínez-Fernández1,2, N Sáinz2, P L Prieto-Hontoria1, M A Burrell4, C M Rodríguez-Ortigosa5,6, J A Martínez1,2,3,7, M J Moreno-Aliaga1,2,3,7. 1. University of Navarra, Department of Nutrition, Food Science and Physiology, Pamplona, Spain. 2. University of Navarra, Centre for Nutrition Research, Pamplona, Spain. 3. Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. 4. University of Navarra, Department of Histology and Pathology, Pamplona, Spain. 5. Hepatology Program, Center for Applied Medical Research, University of Navarra, Pamplona, Spain. 6. Biomedical Research Centre for Hepatic and Digestive Diseases (CIBERehd), Institute of Health Carlos III (ISCIII), Madrid, Spain. 7. Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III (ISCIII), Madrid, Spain.
Abstract
BACKGROUND/ OBJECTIVES: The aim of this study was to characterize the effects of Maresin 1 (MaR1) in obesity-related liver steatosis and the mechanisms involved. METHODS: MaR1 effects on fatty liver disease were tested in ob/ob (2-10 μg kg-1 i.p., 20 days) and in diet-induced obese (DIO) mice (2 μg kg-1, i.p., or 50 μg kg-1, oral gavage for 10 days), as well as in cultured hepatocytes. RESULTS: In ob/ob mice, MaR1 reduced liver triglycerides (TG) content, fatty acid synthase (FAS) and stearoyl-CoA desaturase-1 protein expression, while increased acetyl-CoA carboxylase (ACC) phosphorylation and LC3II protein expression, in parallel with a drop in p62 levels. Similar effects on hepatic TG, ACC phosphorylation, p62 and LC3II were observed in DIO mice after MaR1 i.p. injection. Interestingly, oral gavage of MaR1 also decreased serum transaminases, reduced liver weight and TG content. MaR1-treated mice exhibited reduced hepatic lipogenic enzymes content (FAS) or activation (by phosphorylation of ACC), accompanied by upregulation of carnitine palmitoyltransferase (Cpt1a), acyl-coenzyme A oxidase (Acox1) and autophagy-related proteins 5 and 7 (Atg5-7) gene expression, along with increased number of autophagic vacuoles and reduced p62 protein levels. MaR1 also induced AMP-activated protein kinase (AMPK) phosphorylation in DIO mice and in primary hepatocytes, and AMPK inhibition completely blocked MaR1 effects on Cpt1a, Acox1, Atg5 and Atg7 expression. CONCLUSIONS: MaR1 ameliorates liver steatosis by decreasing lipogenic enzymes, while inducing fatty acid oxidation genes and autophagy, which could be related to AMPK activation. Thus, MaR1 may be a new therapeutic candidate for reducing fatty liver in obesity.
BACKGROUND/ OBJECTIVES: The aim of this study was to characterize the effects of Maresin 1 (MaR1) in obesity-related liver steatosis and the mechanisms involved. METHODS: MaR1 effects on fatty liver disease were tested in ob/ob (2-10 μg kg-1 i.p., 20 days) and in diet-induced obese (DIO) mice (2 μg kg-1, i.p., or 50 μg kg-1, oral gavage for 10 days), as well as in cultured hepatocytes. RESULTS: In ob/ob mice, MaR1 reduced liver triglycerides (TG) content, fatty acid synthase (FAS) and stearoyl-CoA desaturase-1 protein expression, while increased acetyl-CoA carboxylase (ACC) phosphorylation and LC3II protein expression, in parallel with a drop in p62 levels. Similar effects on hepatic TG, ACC phosphorylation, p62 and LC3II were observed in DIO mice after MaR1 i.p. injection. Interestingly, oral gavage of MaR1 also decreased serum transaminases, reduced liver weight and TG content. MaR1-treated mice exhibited reduced hepatic lipogenic enzymes content (FAS) or activation (by phosphorylation of ACC), accompanied by upregulation of carnitine palmitoyltransferase (Cpt1a), acyl-coenzyme A oxidase (Acox1) and autophagy-related proteins 5 and 7 (Atg5-7) gene expression, along with increased number of autophagic vacuoles and reduced p62 protein levels. MaR1 also induced AMP-activated protein kinase (AMPK) phosphorylation in DIO mice and in primary hepatocytes, and AMPK inhibition completely blocked MaR1 effects on Cpt1a, Acox1, Atg5 and Atg7 expression. CONCLUSIONS: MaR1 ameliorates liver steatosis by decreasing lipogenic enzymes, while inducing fatty acid oxidation genes and autophagy, which could be related to AMPK activation. Thus, MaR1 may be a new therapeutic candidate for reducing fatty liver in obesity.
Authors: L M Laiglesia; S Lorente-Cebrián; P L Prieto-Hontoria; M Fernández-Galilea; S M R Ribeiro; N Sáinz; J A Martínez; M J Moreno-Aliaga Journal: J Nutr Biochem Date: 2016-08-26 Impact factor: 6.048
Authors: Tomas Jelenik; Martin Rossmeisl; Ondrej Kuda; Zuzana Macek Jilkova; Dasa Medrikova; Vladimir Kus; Michal Hensler; Petra Janovska; Ivan Miksik; Marcin Baranowski; Jan Gorski; Sophie Hébrard; Thomas E Jensen; Pavel Flachs; Simon Hawley; Benoit Viollet; Jan Kopecky Journal: Diabetes Date: 2010-08-06 Impact factor: 9.461
Authors: Gabriela Salim de Castro; Rafael Deminice; Livia Maria Cordeiro Simões-Ambrosio; Philip C Calder; Alceu A Jordão; Helio Vannucchi Journal: Mar Drugs Date: 2015-04-01 Impact factor: 5.118
Authors: Phillip J White; Philippe St-Pierre; Alexandre Charbonneau; Patricia L Mitchell; Emmanuelle St-Amand; Bruno Marcotte; André Marette Journal: Nat Med Date: 2014-05-11 Impact factor: 53.440
Authors: María José Rodríguez; Matías Sabaj; Gerardo Tolosa; Francisca Herrera Vielma; María José Zúñiga; Daniel R González; Jessica Zúñiga-Hernández Journal: Cells Date: 2021-12-03 Impact factor: 6.600